Showing results (161-170 of 277) with videos related to

Sort By:
Pageof 28
Journal for Immunotherapy of Cancer|June 20, 2020
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE<sub>2</sub>-receptor E-type 4 (EP4), in patients with advanced cancersDavid S Hong, Aparna Parikh, Geoffrey I Shapiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2017
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Carcinoma or Other Solid TumorsRebecca Kristeleit, Geoffrey I Shapiro, Howard A Burris, et al.
Nature Communications|January 6, 2025
MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trialMrinal Gounder, Melissa Johnson, Rebecca S Heist, et al.
Biorxiv : the Preprint Server for Biology|June 26, 2025
Disruption of Microhomology-mediated End-joining in Ewing SarcomaShuhei Asada, Guangli Zhu, Jithma Prasad Abeykoon, et al.
JCO Precision Oncology|October 24, 2024
Multiomic Characterization and Molecular Profiling of Nuclear Protein in Testis CarcinomaGianna Kroening, Jia Luo, Mark G Evans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2012
Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancerTakeshi Shimamura, Samanthi A Perera, Kevin P Foley, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 3, 2013
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistanceNeil Johnson, Shawn F Johnson, Wei Yao, et al.
Future Oncology (London, England)|January 18, 2022
CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burdenCharles Peterfy, Yan Chen, Peter Countryman, et al.
Cancers|September 9, 2022
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a TrialJohn Hilton, Mihaela Cristea, Sophie Postel-Vinay, et al.
Cancer Research|October 11, 2023
The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT CarcinomaR Taylor Durall, Julianna Huang, Luke Wojenski, et al.
Pageof 28